File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: NDUFB7 mutations cause brain neuronal defects, lactic acidosis, and mitochondrial dysfunction in humans and zebrafish

TitleNDUFB7 mutations cause brain neuronal defects, lactic acidosis, and mitochondrial dysfunction in humans and zebrafish
Authors
Issue Date1-Mar-2025
PublisherSpringer Nature
Citation
Cell Death Discovery, 2025, v. 11, n. 1 How to Cite?
AbstractComplex I of the mitochondrial electron transfer chain is one of the largest membrane protein assemblies ever discovered. A patient carrying a homozygous NDUFB7 intronic mutation died within two months after birth due to cardiorespiratory defects, preventing further study. Here, we report another patient with compound heterozygous mutations in NDUFB7 who suffers from pons abnormality, lactic acidosis, prematurity, prenatal and postnatal growth deficiency, incomplete closure of the abdominal wall (ventral hernia), and a poorly functioning gastrointestinal tract (pseudo-obstruction). We demonstrated that the patient’s skin fibroblasts are deficient in Complex I assembly and reduced supercomplex formation. This report further broadens the spectrum of mitochondrial disorders. The patient has had several surgeries. After receiving treatment with Coenzyme Q10 and vitamin B complex, she has remained stable up to this point. To further explore the functionality of NDUFB7 in vivo, we knocked down Ndufb7 in zebrafish embryos. This resulted in brain ventricle and neuronal defects, elevated lactic acid levels, and reduced oxygen consumption, indicating defective mitochondrial respiration. These phenotypes can be specifically rescued by ectopic expression of ndufb7. More importantly, Mitoquinone mesylate (MitoQ), a common remedy for mitochondrial disorders, can ameliorate these conditions. These results suggest a role for NDUFB7 in mitochondrial activity and the suitability of the zebrafish model for further drug screening and the development of therapeutic strategies for this rare disease.
Persistent Identifierhttp://hdl.handle.net/10722/355304

 

DC FieldValueLanguage
dc.contributor.authorChen, Yen Lin-
dc.contributor.authorChung, Brian Hon Yin-
dc.contributor.authorMimaki, Masakazu-
dc.contributor.authorUchino, Shumpei-
dc.contributor.authorChien, Yin Hsiu-
dc.contributor.authorMak, Christopher Chun Yu-
dc.contributor.authorPeng, Steven Shinn Forng-
dc.contributor.authorWang, Wei Chen-
dc.contributor.authorLin, Yu Li-
dc.contributor.authorHwu, Wuh Liang-
dc.contributor.authorLee, Shyh Jye-
dc.contributor.authorLee, Ni Chung-
dc.date.accessioned2025-04-02T00:35:15Z-
dc.date.available2025-04-02T00:35:15Z-
dc.date.issued2025-03-01-
dc.identifier.citationCell Death Discovery, 2025, v. 11, n. 1-
dc.identifier.urihttp://hdl.handle.net/10722/355304-
dc.description.abstractComplex I of the mitochondrial electron transfer chain is one of the largest membrane protein assemblies ever discovered. A patient carrying a homozygous NDUFB7 intronic mutation died within two months after birth due to cardiorespiratory defects, preventing further study. Here, we report another patient with compound heterozygous mutations in NDUFB7 who suffers from pons abnormality, lactic acidosis, prematurity, prenatal and postnatal growth deficiency, incomplete closure of the abdominal wall (ventral hernia), and a poorly functioning gastrointestinal tract (pseudo-obstruction). We demonstrated that the patient’s skin fibroblasts are deficient in Complex I assembly and reduced supercomplex formation. This report further broadens the spectrum of mitochondrial disorders. The patient has had several surgeries. After receiving treatment with Coenzyme Q10 and vitamin B complex, she has remained stable up to this point. To further explore the functionality of NDUFB7 in vivo, we knocked down Ndufb7 in zebrafish embryos. This resulted in brain ventricle and neuronal defects, elevated lactic acid levels, and reduced oxygen consumption, indicating defective mitochondrial respiration. These phenotypes can be specifically rescued by ectopic expression of ndufb7. More importantly, Mitoquinone mesylate (MitoQ), a common remedy for mitochondrial disorders, can ameliorate these conditions. These results suggest a role for NDUFB7 in mitochondrial activity and the suitability of the zebrafish model for further drug screening and the development of therapeutic strategies for this rare disease.-
dc.languageeng-
dc.publisherSpringer Nature-
dc.relation.ispartofCell Death Discovery-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleNDUFB7 mutations cause brain neuronal defects, lactic acidosis, and mitochondrial dysfunction in humans and zebrafish-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41420-025-02369-0-
dc.identifier.scopuseid_2-s2.0-85219628554-
dc.identifier.volume11-
dc.identifier.issue1-
dc.identifier.eissn2058-7716-
dc.identifier.issnl2058-7716-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats